Evidence map›Paper›PMID 39983715›Full record

Trial reportCell reports. Medicine2025

Continuous replenishment of the dysfunctional CD8 T cell axis is associated with response to chemoimmunotherapy in advanced breast cancer.

Christina Metoikidou, Vadim Karnaukhov, Bram Boeckx, Eleonora Timperi, Pierre-Emmanuel Bonté, Ling Wang, Marion Espenel, Benoit Albaud, Delphine Loirat, Xiaoxiao Wang and 15 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. γδ T cells show distinct responses to CMV after stem cell transplantation.Journal of molecular medicine (Berlin, Germany) · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Christina MetoikidouInstitut Curie, PSL University, Inserm U932, Immunity and Cancer, 75005 Paris, France; Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Vadim KarnaukhovInstitut Curie, PSL University, Inserm U932, Immunity and Cancer, 75005 Paris, France; Laboratoire de Physique de l'École Normale Supérieure, Paris Sciences & Lettres University, CNRS, Sorbonne Université and Université Paris Cité, 75005 Paris, France.
Bram BoeckxLaboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium; VIB Center for Cancer Biology, Leuven, Belgium.
Eleonora TimperiInstitut Curie, PSL University, Inserm U932, Immunity and Cancer, 75005 Paris, France.
Pierre-Emmanuel BontéInstitut Curie, PSL University, Inserm U932, Immunity and Cancer, 75005 Paris, France.
Ling WangLaboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium; VIB Center for Cancer Biology, Leuven, Belgium.
Marion EspenelInstitut Curie Genomics of Excellence (ICGex) Platform, Institut Curie, 75005 Paris, France.
Benoit AlbaudInstitut Curie Genomics of Excellence (ICGex) Platform, Institut Curie, 75005 Paris, France.
Delphine LoiratDepartment of Medical Oncology, Center for Cancer Immunotherapy, Institut Curie, Paris, France.
Xiaoxiao WangInstitut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Christos SotiriouInstitut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Philippe AftimosInstitut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Kevin PunieDepartment of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium.
Hans WildiersDepartment of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium.
Viktorija LabroskaThe National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Ming-Wei WangThe National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Joshua J WaterfallTranslational Research Department, Institut Curie, 75005 Paris, France; INSERM U830, Institut Curie, 75005 Paris, France.
Martine Piccart-GebhartInstitut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Thierry MoraLaboratoire de Physique de l'École Normale Supérieure, Paris Sciences & Lettres University, CNRS, Sorbonne Université and Université Paris Cité, 75005 Paris, France.
Aleksandra WalczakLaboratoire de Physique de l'École Normale Supérieure, Paris Sciences & Lettres University, CNRS, Sorbonne Université and Université Paris Cité, 75005 Paris, France.
Olivier LantzInstitut Curie, PSL University, Inserm U932, Immunity and Cancer, 75005 Paris, France; Laboratoire d'immunologie clinique, Institut Curie, 75005 Paris, France; Centre d'investigation Clinique en Biothérapie Gustave-Roussy Institut Curie (CIC-BT1428), Paris, France.
Laurence BuisseretInstitut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Diether LambrechtsLaboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium; VIB Center for Cancer Biology, Leuven, Belgium.
Sebastian AmigorenaInstitut Curie, PSL University, Inserm U932, Immunity and Cancer, 75005 Paris, France.
Emanuela RomanoInstitut Curie, PSL University, Inserm U932, Immunity and Cancer, 75005 Paris, France; Department of Medical Oncology, Center for Cancer Immunotherapy, Institut Curie, Paris, France. Electronic address: emanuela.romano@curie.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy combined with immune checkpoint blockade has shown clinical activity in breast cancer. Response, however, occurs in only a low proportion of patients. How the immune landscape of the tumor determines the immune and clinical responses to chemoimmunotherapy is not well understood. Here, using a combination of single-cell RNA sequencing (scRNA-seq) and single-cell T cell receptor sequencing (scTCR-seq), we profile 40 biopsies from 27 patients with metastatic triple-negative breast cancer (TNBC), receiving chemotherapy and anti-PD-L1 alone or in combination with anti-CD73, in a phase 2 randomized clinical trial. Our results show an enrichment of late-dysfunctional, clonally expanded CD8

Indexed as

Breast NeoplasmsCD8-Positive T-LymphocytesImmunotherapyTriple Negative Breast NeoplasmsAgedFemaleHumansImmune Checkpoint InhibitorsMiddle AgedSingle-Cell AnalysisImmune Checkpoint Inhibitorsanti-CD73anti-PD(L)1CD8chemo-immunotherapyresponse to chemo-immunotherapyT cell clonal dynamicsT cell clonalityT cellsTCR repertoiretriple-negative breast cancer

Identifiers

PMID39983715
PMCPMC11970331

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.